AML Hotline: Utilizing Mutations to Individualize Therapy for Patients with Acute Myeloid Leukemia
Release Date: March 4, 2019
This activity is for clinicians who treat patients with AML: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals.
After completing this activity, participants should be better able to:
- Describe how a comprehensive genomic assessment, including cytogenetics and molecular assessment, is necessary for optimal classification and prognosis of patients with AML
- Identify how knowledge of functional AML subsets can be used to inform selection of currently available therapeutic strategies
- Assess recent data of emerging therapeutic options for patients with AML, including advances in chemotherapies, hypomethylating agents, targeted therapies, immunotherapies, and other approaches
- Evaluate alternative strategies, including clinical trial participation, for patients with AML that are unlikely to benefit from standard chemotherapeutic approaches
Method of Participation
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through March 4, 2020.
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality. All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:
Harry P. Erba, MD, PhD
Professor of Medicine
Director of Leukemia Program
Division of Hematologic Malignancies and Cellular Therapy
Durham, North Carolina
Consulting Fees: Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals, MacroGenics, Inc., Novartis, Pfizer, Inc., Seattle Genetics, Inc.
Scientific Steering Committee: Daiichi Sankyo, Inc.
Speakers Bureau: Agios Pharmaceuticals, Inc., Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals, Novartis
Educational grant support provided by AbbVie Inc., Agios Pharmaceuticals, Inc., and Daiichi Sankyo, Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.